The relative factors of CRP and prediction of major adverse cardiac events for coronary disease.
冠心病病人CRP的影响因素及对主要不良心脏事件的预测。
Medicine treatment plays key role in reducing the rate of restenosis and major adverse cardiac events.
药物治疗是减少冠心病介入术后支架内再狭窄、降低远期主要心血管事件的主要手段。
The relative factors of CRP and prediction of major adverse cardiac events (MACE) for coronary disease (CHD).
冠心病病人CRP的影响因素及对主要不良心脏事件（MACE）的预测。
Total incidence of major adverse cardiac events in hypokalemia group(23.8%) was higher than that in normal potassium group(15.8%).
低血钾组总的严重不良事件发生率（23.8%）明显高于正常血钾组（15.8%）。
The incidence rate of major adverse cardiac events (MACE) was not significantly different between the two groups during hospitalization.
两组住院期间心血管病事件发生率无明显统计学差别。
ResultsFor follow-up 47 patients, the mortality, target vessel revascularization ratio and major adverse cardiac events were 2.1%, 2.1%, 6.4%.
结果对47例患者进行随访，病死率、靶血管重建率和主要心脏事件发生率分别为2.1%、2.1%和6.4%。
Major adverse cardiac events (cardiac death, acute myocardial infarction and recurrent angina) and the use of nitrates were recorded during follow-up.
随访不良心脏事件(死亡、急性心肌梗死和心绞痛复发)发生和硝酸酯类药物应用情况。
Coronary angiography was performed at the 6th month. The late lumen loss, stent restenosis and major adverse cardiac events were compared in both groups.
术后6个月重复冠状动脉造影，比较两组间的晚期管腔丢失、支架再狭窄率及术后心血管不良事件发生率。
The primary end point used was major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), stroke and target vessel revascularization (TVR).
主要终点为主要不良心血管事件（MACE），定义为死亡，心肌梗塞（MI），休克和靶血管血运重建（TVR）。
The primary end point used was major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), stroke and target vessel revascularization (TVR).
主要终点为主要不良心血管事件（MACE），定义为死亡，心肌梗塞（MI），休克和靶血管血运重建（TVR）。
应用推荐